Twilight Litaka Pharma Ltd
Twilight Litaka Pharma Limited, incorporated in India, Listed on the Bombay Stock exchange Limited, and National Stock Exchange Limited, the company is engaged in Pharmaceuticals business
- Market Cap ₹ Cr.
- Current Price ₹ 2.88
- High / Low ₹ /
- Stock P/E
- Book Value ₹ -55.8
- Dividend Yield 0.00 %
- ROCE -5.36 %
- ROE %
- Face Value ₹ 5.00
Pros
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -38.9% over past five years.
- Company has high debtors of 2,342 days.
- Working capital days have increased from 467 days to 1,003 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Jun 2013 15m | Jun 2014 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| 155 | 197 | 295 | 370 | 492 | 657 | 730 | 338 | 32 | 13 | |
| 139 | 171 | 257 | 322 | 425 | 559 | 662 | 379 | 40 | 11 | |
| Operating Profit | 16 | 27 | 38 | 49 | 67 | 98 | 69 | -41 | -9 | 2 |
| OPM % | 10% | 13% | 13% | 13% | 14% | 15% | 9% | -12% | -28% | 15% |
| 2 | 1 | 2 | 3 | 3 | 3 | -14 | -114 | -127 | -144 | |
| Interest | 6 | 7 | 12 | 21 | 26 | 34 | 45 | 1 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 3 | 3 | 4 | 5 | 6 | 5 | 5 |
| Profit before tax | 10 | 19 | 27 | 28 | 41 | 63 | 4 | -162 | -141 | -147 |
| Tax % | 7% | 26% | 32% | 22% | 20% | 22% | 21% | 0% | 0% | |
| 10 | 14 | 18 | 22 | 33 | 49 | 4 | -162 | -141 | -147 | |
| EPS in Rs | 1.42 | -65.52 | -56.91 | -59.41 | ||||||
| Dividend Payout % | 0% | 8% | 12% | 10% | 10% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -39% |
| 3 Years: | -64% |
| TTM: | -68% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 94% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Jun 2013 | Jun 2014 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 11 | 11 | 11 | 11 | 11 | 12 | 12 | 12 |
| Reserves | 5 | 24 | 40 | 59 | 95 | 144 | 169 | 6 | -133 |
| 58 | 67 | 120 | 160 | 195 | 258 | 302 | 307 | 307 | |
| 43 | 29 | 48 | 55 | 59 | 66 | 68 | 117 | 129 | |
| Total Liabilities | 114 | 131 | 219 | 285 | 360 | 478 | 551 | 442 | 315 |
| 35 | 30 | 34 | 58 | 67 | 81 | 95 | 88 | 83 | |
| CWIP | 0 | 0 | 7 | 5 | 10 | 7 | 7 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 11 | 11 | 11 | 11 |
| 79 | 101 | 177 | 221 | 283 | 379 | 438 | 344 | 220 | |
| Total Assets | 114 | 131 | 219 | 285 | 360 | 478 | 551 | 442 | 315 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Jun 2013 | Jun 2014 | |
|---|---|---|---|---|---|---|---|---|---|
| -7 | -2 | -16 | 5 | 14 | -5 | 2 | -6 | 2 | |
| -1 | -1 | -25 | -25 | -30 | -25 | -19 | 0 | -0 | |
| 9 | 3 | 42 | 21 | 17 | 27 | 16 | 4 | -1 | |
| Net Cash Flow | 0 | 0 | 0 | 2 | 2 | -3 | -1 | -2 | 1 |
| Free Cash Flow | -8 | -3 | -29 | -20 | -3 | -20 | -17 | -6 | 1 |
| CFO/OP | -39% | 10% | -20% | 23% | 32% | 2% | 3% | 12% | -21% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Jun 2013 | Jun 2014 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 119 | 125 | 140 | 141 | 133 | 143 | 163 | 278 | 2,342 |
| Inventory Days | 57 | 58 | 59 | 68 | 67 | 61 | 50 | 68 | 75 |
| Days Payable | 50 | 44 | 41 | 35 | 33 | 29 | 22 | 32 | 434 |
| Cash Conversion Cycle | 127 | 139 | 159 | 174 | 166 | 175 | 191 | 314 | 1,983 |
| Working Capital Days | 110 | 131 | 159 | 164 | 165 | 161 | 174 | 224 | 1,003 |
| ROCE % | 30% | 28% | 25% | 25% | 27% | 14% | -12% | -5% |